Inspra

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It is prescribed to lower blood pressure in hypertension and to improve outcomes in adults with heart failure by selectively blocking aldosterone receptors, reducing sodium retention and potassium loss, and supporting cardiovascular health.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets.

Eplerenone is used in conditions where excess aldosterone contributes to cardiovascular disease. Hypertension: lowers systolic and diastolic blood pressure in adult patients. Heart failure: reduces risk of hospitalization and cardiovascular death in patients with reduced ejection fraction. Post‑myocardial infarction with left‑ventricular dysfunction: helps prevent progression of heart failure after an acute coronary event.

Eplerenone may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Dizziness: sensation of light‑headedness, especially on standing. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute renal failure or worsening of existing renal impairment. - Angioedema: rapid swelling of face, lips, or airway. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing eplerenone, clinicians should consider several safety measures. Monitor serum potassium: check levels before initiation and periodically during therapy. Assess renal function: evaluate creatinine clearance prior to and during treatment. Use caution in diabetes: patients have an increased risk of hyperkalemia. Avoid in severe hepatic impairment: drug metabolism may be compromised. Contraindicated in hyperkalemia: do not use if serum potassium exceeds 5.0 mEq/L. Store at room temperature: keep in the original packaging, protect from moisture and light.

Eplerenone can interact with other medicines, altering potassium balance or renal function.

Major Interactions (Avoid): - ACE inhibitors and ARBs: combined use may cause dangerous hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): additive effect on potassium. - Potassium supplements: increase risk of hyperkalemia. - Trimethoprim‑sulfamethoxazole: may raise potassium levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal clearance and raise potassium. - Digoxin: increased risk of toxicity in renal impairment. - Lithium: altered lithium clearance; monitor serum levels.